SCHEMBL22130676

SCHEMBL22130676

CC(=O)NCC1=Cc2c(c(-c3ccccc3)nn2S(=O)(=O)c2ccccc2)C(=O)C1=O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ PTGDR2 Q9Y5Y4 1/20 0.37
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ LMNA P02545 3/20 0.35
▸ HTT P42858 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ PKM P14618 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ MCOLN3 Q8TDD5 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ MAPT P10636 3/20 0.35
▸ ELAVL1 Q15717 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22130678 0.84 MEN1 (0.39) PTGDR2MEN1KMT2ALMNAHTT
SCHEMBL22130708 0.82 KDM4E (0.39) KDM4ERXFP1PTGDR2MEN1KMT2A
SCHEMBL22130646 0.78 ELAVL1 (0.56) MEN1KMT2ALMNAELAVL1
SCHEMBL22130735 0.78 HPGD (0.41) PTGDR2MEN1KMT2ALMNAHTT
SCHEMBL22130677 0.73 MEN1 (0.39) KDM4EPTGDR2MEN1KMT2ALMNA
SCHEMBL22130726 0.72 ELAVL1 (0.64) MEN1KMT2ALMNAHTTALDH1A1
SCHEMBL22130653 0.72 ELAVL1 (0.58) KDM4EMEN1KMT2ALMNAHTT
SCHEMBL22130647 0.71 ELAVL1 (0.54) KDM4ERXFP1KMT2AELAVL1
SCHEMBL22130679 0.69 MEN1 (0.38) PTGDR2MEN1KMT2ALMNAHTT
SCHEMBL22130733 0.65 HPGD (0.46) PTGDR2MEN1KMT2AHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2020-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy AZI2, TPMT, TYMS KDM4E 374/4885RXFP1 4754/4885PTGDR2 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback